1. Home
  2. IRON vs WLY Comparison

IRON vs WLY Comparison

Compare IRON & WLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$80.06

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo John Wiley & Sons Inc.

WLY

John Wiley & Sons Inc.

HOLD

Current Price

$50.30

Market Cap

2.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRON
WLY
Founded
2017
1807
Country
United States
United States
Employees
N/A
5200
Industry
Biotechnology: Pharmaceutical Preparations
Books
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.1B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
IRON
WLY
Price
$80.06
$50.30
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$103.18
N/A
AVG Volume (30 Days)
812.9K
687.6K
Earning Date
05-07-2026
06-16-2026
Dividend Yield
N/A
3.50%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.04
Revenue Next Year
$283.52
$2.36
P/E Ratio
N/A
$15.84
Revenue Growth
N/A
N/A
52 Week Low
$40.00
$28.38
52 Week High
$99.50
$53.24

Technical Indicators

Market Signals
Indicator
IRON
WLY
Relative Strength Index (RSI) 69.40 66.16
Support Level $70.29 $37.01
Resistance Level $82.70 N/A
Average True Range (ATR) 3.14 2.31
MACD 0.81 0.53
Stochastic Oscillator 73.44 77.78

Price Performance

Historical Comparison
IRON
WLY

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

About WLY John Wiley & Sons Inc.

John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

Share on Social Networks: